HKEX Stock Code: 01093English|繁體|简体
Home > Investor Relations > Announcements & Notices
Announcements & Notices
Dec
21
CONTINUING CONNECTED TRANSACTIONS - LEASE AGREEMENTS
Dec
17
VOLUNTARY ANNOUNCEMENT - PRODUCT LICENSING AND COMMERCIALIZATION AGREEMENT
Dec
11
PROGRESS UPDATE ON THE PROPOSED SPIN-OFF AND SEPARATE LISTING OF CSPC XNW GROUP ON THE SHENZHEN STOCK EXCHANGE
Nov
26
VOLUNTARY ANNOUNCEMENT - PASSING OF CONSISTENCY EVALUATION FOR THE GROUP'S "AMOXICILLIN CAPSULES"
Nov
26
VOLUNTARY ANNOUNCEMENT - THE GROUP'S "TIROFIBAN HYDROCHLORIDE AND SODIUM CHLORIDE INJECTION" WAS GRANTED DRUG REGISTRATION APPROVAL
Nov
26
VOLUNTARY ANNOUNCEMENT - THE GROUP'S PRODUCT CANDIDATE "ALMB-0166" WAS GRANTED ORPHAN-DRUG DESIGNATION BY THE U.S. FDA
Nov
19
UNAUDITED RESULTS FOR THE NINE MONTHS ENDED 30 SEPTEMBER 2018
Nov
07
DATE OF BOARD MEETING
Nov
01
CONTINUING CONNECTED TRANSACTION - RENEWAL OF MASTER SALES AGREEMENT
Oct
08
VOLUNTARY ANNOUNCEMENT - PRODUCT LICENSE AND COMMERCIALIZATION AGREEMENT
Sep
26
VOLUNTARY ANNOUNCEMENT - PRODUCT LICENSE AND COLLABORATION AGREEMENT
Aug
30
LIST OF DIRECTORS AND THEIR ROLE AND FUNCTION
Aug
30
RESIGNATION OF DIRECTOR
Aug
20
LIST OF DIRECTORS AND THEIR ROLE AND FUNCTION
Aug
20
APPOINTMENT OF EXECUTIVE DIRECTOR AND NON-COMPLIANCE WITH RULE 3.10A OF THE LISTING RULES
Aug
20
ADOPTION OF RESTRICTED SHARE AWARD SCHEME
Aug
20
2018 INTERIM RESULTS ANNOUNCEMENT
Aug
08
DATE OF BOARD MEETING
Aug
06
CONNECTED TRANSACTION - ACQUISITION OF 29.9% EQUITY INTEREST IN CSPC YUANDA (DALIAN) PHARMACEUTICAL CO., LTD.
Jul
23
VOLUNTARY ANNOUNCEMENT - "STATE KEY LABORATORY FOR NOVEL PHARMACEUTICAL PREPARATIONS AND EXCIPIENTS" RATED AS EXCELLENT CLASS OF STATE KEY LABORATORY
Jul
10
VOLUNTARY ANNOUNCEMENT - PRODUCT CO-DEVELOPMENT AND STRATEGIC COLLABORATION AGREEMENT
Jul
10
VOLUNTARY ANNOUNCEMENT - THE GROUP'S INVESTIGATIONAL NEW DRUG "CSPCHA115" WAS GRANTED CLINICAL TRIAL APPROVAL BY THE U.S. FDA
Jul
10
VOLUNTARY ANNOUNCEMENT - PASSING OF CONSISTENCY EVALUATION FOR THE GROUP'S "CAPTOPRIL TABLETS"
Jul
09
LIST OF DIRECTORS AND THEIR ROLE AND FUNCTION
Jul
09
APPOINTMENT OF EXECUTIVE DIRECTOR
Jun
04
VOLUNTARY ANNOUNCEMENT - ADMISSION OF THE GROUP'S "PACLITAXEL FOR INJECTION (ALBUMIN-BOUND)" TO THE "LIST OF MARKETED DRUGS OF CHINA"
May
25
POLL RESULTS OF ANNUAL GENERAL MEETING HELD ON 25 MAY 2018
May
25
LIST OF DIRECTORS AND THEIR ROLE AND FUNCTION
May
25
APPOINTMENT OF VICE-CHAIRMAN AND CHANGE OF ROTATING CHIEF EXECUTIVE OFFICER
May
25
UNAUDITED RESULTS FOR THE THREE MONTHS ENDED 31 MARCH 2018
May
21
VOLUNTARY ANNOUNCEMENT - PASSING OF CONSISTENCY EVALUATION FOR "QIMAITE" (TRAMADOL HYDROCHLORIDE TABLETS)
May
14
DATE OF BOARD MEETING
May
10
VOLUNTARY ANNOUNCEMENT - "Q101-PEGYLATED RECOMBINANT HUMAN INTERFERON-alpha2a FOR INJECTION" FOR THE TREATMENT OF HEPATITIS WAS GRANTED CLINICAL TRIAL APPROVAL
May
10
VOLUNTARY ANNOUNCEMENT - DRUG REGISTRATION APPROVAL OF "DOXOFYLLINE GLUCOSE FOR INJECTION" AND "DOXOFYLLINE SODIUM CHLORIDE FOR INJECTION"
Apr
20
NOTICE OF ANNUAL GENERAL MEETING
Apr
18
VOLUNTARY ANNOUNCEMENT - PRODUCT LICENSING AGREEMENT
Apr
16
VOLUNTARY ANNOUNCEMENT - "VINORELBINE TARTRATE LIPOSOME INJECTION" FOR THE TREATMENT OF LUNG CANCER WAS GRANTED CLINICAL TRIAL APPROVAL
Apr
12
VOLUNTARY ANNOUNCEMENT - PASSING OF CONSISTENCY EVALUATION FOR"WEIHONG"(AZITHROMYCIN TABLETS)
Mar
19
ANNUAL RESULTS FOR THE YEAR ENDED 31 DECEMBER 2017
Mar
16
VOLUNTARY ANNOUNCEMENT - "RECOMBINANT ANTI-EpCAM AND ANTI-CD3 HUMAN-MOUSE CHIMERIC BISPECIFIC ANTIBODY FOR INJECTION" WAS GRANTED DRUG CLINICAL TRIAL APPROVAL
Mar
11
VOLUNTARY ANNOUNCEMENT - THE GROUP'S DRUG "BUTYLPHTHALIDE" WAS GRANTED ORPHAN-DRUG DESIGNATION BY THE U.S. FDA
Mar
07
DATE OF BOARD MEETING
Feb
12
VOLUNTARY ANNOUNCEMENT - DRUG REGISTRATION APPROVAL OF THE GROUP'S "PACLITAXEL FOR INJECTION (ALBUMIN-BOUND)"
Feb
06
VOLUNTARY ANNOUNCEMENT-THE GROUP'S GASTRIC CANCER DRUG "DP303c" WAS GRANTED ORPHAN-DRUG DESIGNATION BY THE U.S. FDA
Jan
09
VOLUNTARY ANNOUNCEMENT - ACQUISITION OF 39.56% EQUITY INTEREST IN WUHAN YZY BIOPHARMA CO., LTD.

Please download the latest "Acrobat Reader" to view the PDF.

© Copyright 2025 CSPC Pharmaceutical Group Limited. All Rights Reserved.
Disclaimer